Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

NCT01730534 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01730534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2013
Completion date
September 11, 2018
Enrollment
17,190 (actual)
Sites
805

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, non-insulin-dependent, high risk for cardiovascular event